Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Updates from a Phase I clinical trial examining ublituximab in combination with TGR-1202

Owen O'Connor • 9 Jun 2016
EHA 2016
B-Cell Lymphoma Non-Hodgkin Lymphoma

Owen O’Connor, MD, PhD from Columbia University Medical Center, New York, NY outlines his presentation on the updates from the Phase I clinical trial examining ublituximab in combination with TGR-1202 for non-Hodgkin lymphoma (NCT02006485). Current results confirmed that the drug is well-tolerated and has a highly favorable safety profile and a continued demonstration of good efficacy in patients with indolent lymphoma, as well as patients with diffuse large B-cell lymphoma (DLBCL). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark

More from Owen O'Connor

Immunoepigenetic platforms for PTCL treatment
6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
PTCL arising as a PTLD: the efficacy of pralatrexate
4:42
PTCL arising as a PTLD: the efficacy of pralatrexate
Owen O'Connor • 19 Jun 2019
The role of epigenetic modulators in the pathogenesis of lymphomas
9:20
The role of epigenetic modulators in the pathogenesis of lymphomas
Anas Younes et al. • 18 Sep 2017
iwNHL 2017: The future of lymphoma research and treatment
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al. • 8 Sep 2017

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals